Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Anthony R. Mato, MD

Anthony R. Mato, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Mato is a Penn Medicine employed physician.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2008
  • Internal Medicine, 2005
  • Medical Oncology, 2008

Clinical Expertise:

  • Chronic Lymphocytic Leukemia (CLL)
  • Lymphoma

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: State University of New York at Buffalo
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American College of Physician Executives, National American Society of Clinical Oncology, National American Society of Hematology, National

Hospital Affiliation

Dr. Mato is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Chadi Nabhan, MD, MBA, FACP; Anthony Mato; Christopher R Flowers; David L Grinblatt; Nicole Lamanna; Mark A Weiss; Matthew S Davids; Arlene S Swern; Shriya Bhushan; Kristen Sullivan; E. Dawn Flick; Pavel Kiselev; Jeff P Sharman: Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: Prospective evaluation on 455 patients treated in the United States BMC Cencer : 2017.

A.R. Mato, B.T. Hill, N. Lamanna, P.M. Barr, C.S. Ujjani, D.M. Brander, C. Howlett, A.P Skarbnik, B.D. Cheson, C.S. Zent, J.J. Pu, P. Kiselev, K. Foon, J. Lenhart, S. Henick Bachow, A.M. Winter, A-L. Cruz, D.F. Claxton, A. Goy, C. Daniel, K. Isaac, K.H. Kennard, C. Timlin, M. Fanning, L. Gashonia, M. Yacur, J. Svoboda, S.J. Schuster and C. Nabhan: Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi- Center Study of 683 Patients Annals of Oncology : 2017.

Nabhan C, Mato AR, Feinberg BA.: Clinical Pathways in Chronic lymphocytic Leukemia: Challenges and Solutions American Journal of Hematology 92 (1): 5-6,2017.

Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB: Ibrutinib Efficacy and Tolerability in Patients with Relapsed Chronic Lymphocytic Leukemia Following Allogeneic HCT Blood 128 (25): 2899-2908,2016.

Anthony Mato, Chadi Nabhan, Neil E. Kay, Mark A. Weiss, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Ian W. Flinn, Mark F. Kozloff, Christopher R. Flowers, Charles M. Farber, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, and Jeff P. Sharman: Real-world clinical experience in the Connect® CLL registry: a prospective cohort study of 1494 patients across 199 US centres British Journal of Hematology 175 (5): 892-903,2016.

Anthony R Mato, Chadi Nabhan, Paul M. Barr, Chaitra S Ujjani, Brian Hill, Nicole Lamanna, Alan Skarbnik, Christina M Howlett, Jeffrey J Pu, Alison Sehgal, Lauren Strelec, Alexandra M Vandegrift, Danielle M Fitzpatrick, Clive S Zent, Tatyana Feldman, Andre H Goy, David Claxton, Spencer H Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita D Nasta, Daniel Landsburg, Stephen Schuster, David L Porter, Bruce D. Cheson, Pavel Kiselev, and Andrew M Evens: Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience BLOOD 128 (18): 2199-2205,2016.

Anthony R Mato, MD MSCE, Colleen Timlin PharmD, Chaitra Ujjani, MD, Alan Skarbnik, MD, Christina Howlett PharmD, Rahul Banerjee, MD, Chadi Nabhan,MD MBA4, Stephen J Schuster, MD: Comparable outcomes in Chronic Lymphocytic Leukemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-center study British Journal of Hematology : 2016.

Prof Susan O'Brien, MD, Jeffrey A Jones, MD, Prof Steven E Coutre, MD, Anthony R Mato, MD, Prof Peter Hillmen, MBChB, Constantine Tam, MD, Prof Anders Österborg, MD, Tanya Siddiqi, MD, Michael J Thirman, MD, Richard R Furman, MD, Prof Osman Ilhan, MD, Prof Michael J Keating, MBBS, Timothy G Call, MD, Jennifer R Brown, MD, Michelle Stevens-Brogan, MSc, Yunfeng Li, PhD, Fong Clow, ScD, Danelle F James, MD, Alvina D Chu, MD, Prof Michael Hallek, MD, Prof Stephan Stilgenbauer, MD: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Lancet Oncology 17 (10): 1409-1418,2016.

Jie Wang, Jennifer Morrissette, David B Lieberman, Colleen Timlin, Stephen Schuster, Anthony R Mato: Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations in Chronic Lymphocytic Leukemia British Journal of Hematology : 2016.

Spencer Bachow, Chadi Nabhan, Anthony Mato, Christopher Flowers, Neil Kay, David Grinblatt, Matthew Davids, Mark Weiss, Kristen Sullivan, E Dawn Flick, Pavel Kiselev, Shriya Bhushan, Arlene Swern, Jeff Sharman, Nicole Lamanna: Characteristics and Outcomes in Women and Men in the Connect® CLL Registry Clinical lymphoma, leukemia and myeloma 16 (2): S43-S44,2016.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-160
3400 Civic Center Blvd

Philadelphia, PA 19146
Phone: (215) 615-7361
Fax: (215) 615-5888
Patient appointments: 800-789-PENN (7366)

Related Links